These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24365577)

  • 1. The pharmacogenomics of statins.
    Gelissen IC; McLachlan AJ
    Pharmacol Res; 2014 Oct; 88():99-106. PubMed ID: 24365577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
    Generaux GT; Bonomo FM; Johnson M; Doan KM
    Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy.
    Couvert P; Chapman MJ; Carrié A
    Pharmacogenomics; 2011 Feb; 12(2):137-9. PubMed ID: 21332305
    [No Abstract]   [Full Text] [Related]  

  • 4. An update on efflux and uptake transporters as determinants of statin response.
    Rocha KCE; Pereira BMV; Rodrigues AC
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):613-624. PubMed ID: 29842801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacogenetic analysis can predict adverse effects of statins].
    Garwicz D; Wadelius M
    Lakartidningen; 2013 May 7-21; 110(19-20):951-2. PubMed ID: 23745502
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenomics and adverse drug reactions: the case of statins.
    Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
    Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efflux and uptake transporters as determinants of statin response.
    Rodrigues AC
    Expert Opin Drug Metab Toxicol; 2010 May; 6(5):621-32. PubMed ID: 20367534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.
    Elsby R; Hilgendorf C; Fenner K
    Clin Pharmacol Ther; 2012 Nov; 92(5):584-98. PubMed ID: 23047648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins and skeletal muscles toxicity: from clinical trials to everyday practice.
    Norata GD; Tibolla G; Catapano AL
    Pharmacol Res; 2014 Oct; 88():107-13. PubMed ID: 24835295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.
    Meyer zu Schwabedissen HE; Albers M; Baumeister SE; Rimmbach C; Nauck M; Wallaschofski H; Siegmund W; Völzke H; Kroemer HK
    Pharmacogenet Genomics; 2015 Jan; 25(1):8-18. PubMed ID: 25379722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting response to statins by pharmacogenetic testing.
    Gelissen IC; Brown AJ
    Pharmacogenomics; 2012 Aug; 13(11):1223-5. PubMed ID: 22920392
    [No Abstract]   [Full Text] [Related]  

  • 12. A current approach to statin intolerance.
    Tompkins R; Schwartzbard A; Gianos E; Fisher E; Weintraub H
    Clin Pharmacol Ther; 2014 Jul; 96(1):74-80. PubMed ID: 24727470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy].
    Dendramis G
    G Ital Cardiol (Rome); 2011 Mar; 12(3):182-5. PubMed ID: 21560474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
    Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific considerations on the prescription and therapeutic interchange of statins].
    García-Sabina A; Gulín-Dávila J; Sempere-Serrano P; González-Juanatey C; Martínez-Pacheco R
    Farm Hosp; 2012; 36(2):97-108. PubMed ID: 21820929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Langmann T
    Vascul Pharmacol; 2006 Feb; 44(2):75-89. PubMed ID: 16337220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacogenetics of statin therapy: when the body aches, the mind will follow.
    Rossi JS; McLeod HL
    J Am Coll Cardiol; 2009 Oct; 54(17):1617-8. PubMed ID: 19833261
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenomics and drug toxicity.
    Nakamura Y
    N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
    [No Abstract]   [Full Text] [Related]  

  • 19. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
    Hubacek JA; Dlouha D; Adámkova V; Lanska V; Ceska R; Vrablik M
    Neuro Endocrinol Lett; 2012; 33 Suppl 2():22-5. PubMed ID: 23183505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLCO1B1 variants and statin-induced myopathy.
    Vladutiu GD; Isackson PJ
    N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.